TMS denied as experimental or investigational by Cigna?

Cigna's specific coverage criteria for tms are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Cigna Denies TMS as Experimental — and Why That Denial Is Challengeable

Cigna may classify Transcranial Magnetic Stimulation (TMS) as experimental, investigational, or unproven, particularly for indications beyond major depressive disorder (such as OCD, PTSD, or smoking cessation). The strength of this denial depends heavily on which indication is at issue. For FDA-cleared indications, an experimental denial is factually contestable. For indications that are not yet FDA-cleared, the appeal must rely on a different argument: that the treatment meets Cigna's specific criteria for an exception to the experimental exclusion.

## Two Different Situations, Two Different Appeals

If your indication is FDA-cleared: TMS has received FDA 510(k) clearance for major depressive disorder and certain other indications. For a cleared indication, Cigna's experimental classification contradicts federal regulatory status. Your appeal should lead with the FDA clearance documentation and make clear that "experimental" cannot apply to a device cleared by FDA for the specific use being sought.

If your indication is not yet FDA-cleared: Your appeal must argue under Cigna's "off-label" or "emerging therapy" exception criteria, which typically require evidence of professional society endorsement and peer-reviewed support. Your treating clinician's letter is central here.

## Your Federal Appeal Rights

• Internal appeal (ERISA §503 / ACA §2719): File within the timeframe on your denial notice. Specify whether the denial is for an FDA-cleared indication or an off-label use, and tailor your evidence accordingly.
• External review (ACA §2719): Experimental or investigational denials are among the most frequently reviewed by Independent Review Organizations (IROs). The window is generally around four months from the final internal denial.
• Expedited review: Available when your treating provider certifies that your condition is urgent.

## Documentation to Gather

1. FDA clearance documentation — search the FDA 510(k) database for the specific TMS device and indication; attach the clearance summary. 2. Diagnosis confirmation — written diagnosis specifying the indication for which TMS is being requested. 3. Professional guideline organization support — your treating clinician should cite the relevant professional society positions (e.g., American Psychiatric Association, Clinical TMS Society) by name. 4. Treatment history with dates and outcomes — documents why standard treatments were tried and found insufficient, supporting the clinical rationale for TMS. 5. Prescriber medical-necessity letter — addresses Cigna's experimental criteria directly, citing FDA status and guideline support.

## Criteria-Mapping Structure

Review Cigna's current TMS medical coverage policy (available in Cigna's coverage policy portal online). Map each "experimental" criterion:

| Cigna Experimental Criterion | Your Rebuttal | |---|---| | "Not FDA-approved/cleared" | FDA 510(k) clearance summary (if applicable) | | "Insufficient clinical evidence" | Professional society position statement cited by provider | | "Not generally accepted" | Applicable guideline organization's current guidance | | Specific indication match | Diagnosis documentation matching cleared indication |